**Clinical Trial Report: Immunax for Rheumatoid Arthritis**

"A Phase II, double-blind, placebo-controlled clinical trial was conducted to evaluate the efficacy and safety of Immunax in adult patients with moderate-to-severe Rheumatoid Arthritis (RA). The study enrolled 150 patients who were randomly assigned to receive either Immunax (Group A) or a placebo (Group B) for 24 weeks.

Immunax is a monoclonal antibody that targets the **TNF-alpha** protein. This protein is known to be overexpressed in patients with RA, leading to inflammation and joint damage.

The trial's primary endpoint was a 20% improvement in the American College of Rheumatology (ACR20) criteria at week 24. Key secondary endpoints included a reduction in the **DAS28** score and the number of tender and swollen joints.

The patient cohort included individuals with a median age of 52. Among them, **75%** of participants in Group A achieved the primary endpoint, compared to only **25%** in the placebo group. The most common adverse events reported in the Immunax group were mild to moderate injection-site reactions and headaches.

A notable finding from the genetic analysis of the participants was that patients with a specific gene variant, **PTPN22**, showed a more significant therapeutic response to Immunax. This suggests a potential link between the gene and the drug's mechanism of action, which could be a key factor in future patient selection for treatment. The trial showed no new safety signals."